Form 8-K - Current report:
SEC Accession No. 0001213900-25-010723
Filing Date
2025-02-06
Accepted
2025-02-06 07:30:26
Documents
15
Period of Report
2025-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0229937-8k_pluri.htm   iXBRL 8-K 34441
2 FORM OF COMMON WARRANT ea022993701ex4-1_pluri.htm EX-4.1 79467
3 SECURITIES PURCHASE AGREEMENT ea022993701ex10-1_pluri.htm EX-10.1 256854
  Complete submission text file 0001213900-25-010723.txt   626470

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE plur-20250203.xsd EX-101.SCH 3030
5 XBRL LABEL FILE plur-20250203_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE plur-20250203_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0229937-8k_pluri_htm.xml XML 3680
Mailing Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409
Business Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA L3 3508409 972-74-710-7171
Pluri Inc. (Filer) CIK: 0001158780 (see all company filings)

EIN.: 980351734 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31392 | Film No.: 25595462
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)